4//SEC Filing
MORTIMER IAN 4
Accession 0001193125-25-227202
CIK 0001582313other
Filed
Sep 30, 8:00 PM ET
Accepted
Oct 1, 7:17 PM ET
Size
9.6 KB
Accession
0001193125-25-227202
Insider Transaction Report
Form 4
MORTIMER IAN
DirectorPRESIDENT & CEO
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2025-10-01−25,000→ 0 totalExercise: $7.69Exp: 2025-12-17→ Common Shares (25,000 underlying) - Exercise/Conversion
Common Shares
2025-10-01$7.69/sh+25,000$192,250→ 56,302 total - Sale
Common Shares
2025-10-01$40.16/sh−25,000$1,004,000→ 31,302 total
Holdings
- 14,300(indirect: By Spouse)
Common Shares
Footnotes (3)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2024.
- [F2]The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $40.00 to $40.495, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
- [F3]The shares subject to the option are fully vested and exercisable.
Documents
Issuer
Xenon Pharmaceuticals Inc.
CIK 0001582313
Entity typeother
Related Parties
1- filerCIK 0001619961
Filing Metadata
- Form type
- 4
- Filed
- Sep 30, 8:00 PM ET
- Accepted
- Oct 1, 7:17 PM ET
- Size
- 9.6 KB